I Continuing Review

10150, A randomized phase 2 study of bevacizumab and either weekly anetumab ravitansine or weekly paclitaxel in platinum-resistant or platinum refractory ovarian cancer (Protocol Version Date 02/15/19)

II Continuing Review

10220, A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors (Protocol Version Date 11/21/19)

III Amendment

EAY131, Molecular Analysis for Therapy Choice (MATCH) (Protocol Version Date 02/28/20)